Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

John Burn; Anne-Marie Axø Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop; CAPP2 Investigators

doi:10.1016/S0140-6736(11)61049-0

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

John Burn, Anne-Marie Axø Gerdes, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Moeslein, Sylviane Olschwang, Diane Eccles, D Gareth Evans, Eamonn R Maher, Lucio Bertario, Marie-Luise Bisgaard, Malcolm G Dunlop, Judy W C Ho, Shirley V Hodgson, Annika Lindblom, Jan Lubinski, Patrick J Morrison, Victoria Murday, Raj Ramesar, Lucy SideRodney J Scott, Huw J W Thomas, Hans F Vasen, Gail Barker, Gillian Crawford, Faye Elliott, Mohammad Movahedi, Kirsi Pylvanainen, Juul T Wijnen, Riccardo Fodde, Henry T Lynch, John C Mathers, D Timothy Bishop, CAPP2 Investigators

Afdeling for Genetik

780 Citationer (Scopus)

Abstract

Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	378
Udgave nummer	9809
Sider (fra-til)	2081-7
Antal sider	7
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(11)61049-0
Status	Udgivet - 2011

Adgang til dokumentet

10.1016/S0140-6736(11)61049-0

Citationsformater

Burn, J., Gerdes, A-M. A., Macrae, F., Mecklin, J-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., Bisgaard, M-L., Dunlop, M. G., Ho, J. W. C., Hodgson, S. V., Lindblom, A., Lubinski, J., Morrison, P. J., Murday, V., Ramesar, R., ... CAPP2 Investigators (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, 378(9809), 2081-7. https://doi.org/10.1016/S0140-6736(11)61049-0

Burn, J, Gerdes, A-MA, Macrae, F, Mecklin, J-P, Moeslein, G, Olschwang, S, Eccles, D, Evans, DG, Maher, ER, Bertario, L, Bisgaard, M-L, Dunlop, MG, Ho, JWC, Hodgson, SV, Lindblom, A, Lubinski, J, Morrison, PJ, Murday, V, Ramesar, R, Side, L, Scott, RJ, Thomas, HJW, Vasen, HF, Barker, G, Crawford, G, Elliott, F, Movahedi, M, Pylvanainen, K, Wijnen, JT, Fodde, R, Lynch, HT, Mathers, JC, Bishop, DT & CAPP2 Investigators 2011, 'Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial', Lancet, bind 378, nr. 9809, s. 2081-7. https://doi.org/10.1016/S0140-6736(11)61049-0

@article{e91eec7e0e41473697f1633ceaaa0d9f,

title = "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial",

abstract = "Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.",

keywords = "Adenoma, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Chemoprevention, Colorectal Neoplasms, Hereditary Nonpolyposis, Dietary Carbohydrates, Double-Blind Method, Heterozygote, Humans, Starch",

author = "John Burn and Gerdes, {Anne-Marie Ax{\o}} and Finlay Macrae and Jukka-Pekka Mecklin and Gabriela Moeslein and Sylviane Olschwang and Diane Eccles and Evans, {D Gareth} and Maher, {Eamonn R} and Lucio Bertario and Marie-Luise Bisgaard and Dunlop, {Malcolm G} and Ho, {Judy W C} and Hodgson, {Shirley V} and Annika Lindblom and Jan Lubinski and Morrison, {Patrick J} and Victoria Murday and Raj Ramesar and Lucy Side and Scott, {Rodney J} and Thomas, {Huw J W} and Vasen, {Hans F} and Gail Barker and Gillian Crawford and Faye Elliott and Mohammad Movahedi and Kirsi Pylvanainen and Wijnen, {Juul T} and Riccardo Fodde and Lynch, {Henry T} and Mathers, {John C} and Bishop, {D Timothy} and {CAPP2 Investigators}",

year = "2011",

doi = "10.1016/S0140-6736(11)61049-0",

language = "English",

volume = "378",

pages = "2081--7",

journal = "Lancet",

issn = "0140-6736",

publisher = "The/Lancet Publishing Group",

number = "9809",

}

TY - JOUR

T1 - Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

AU - Burn, John

AU - Gerdes, Anne-Marie Axø

AU - Macrae, Finlay

AU - Mecklin, Jukka-Pekka

AU - Moeslein, Gabriela

AU - Olschwang, Sylviane

AU - Eccles, Diane

AU - Evans, D Gareth

AU - Maher, Eamonn R

AU - Bertario, Lucio

AU - Bisgaard, Marie-Luise

AU - Dunlop, Malcolm G

AU - Ho, Judy W C

AU - Hodgson, Shirley V

AU - Lindblom, Annika

AU - Lubinski, Jan

AU - Morrison, Patrick J

AU - Murday, Victoria

AU - Ramesar, Raj

AU - Side, Lucy

AU - Scott, Rodney J

AU - Thomas, Huw J W

AU - Vasen, Hans F

AU - Barker, Gail

AU - Crawford, Gillian

AU - Elliott, Faye

AU - Movahedi, Mohammad

AU - Pylvanainen, Kirsi

AU - Wijnen, Juul T

AU - Fodde, Riccardo

AU - Lynch, Henry T

AU - Mathers, John C

AU - Bishop, D Timothy

AU - CAPP2 Investigators

PY - 2011

Y1 - 2011

N2 - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

AB - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

KW - Adenoma

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Aspirin

KW - Chemoprevention

KW - Colorectal Neoplasms, Hereditary Nonpolyposis

KW - Dietary Carbohydrates

KW - Double-Blind Method

KW - Heterozygote

KW - Humans

KW - Starch

U2 - 10.1016/S0140-6736(11)61049-0

DO - 10.1016/S0140-6736(11)61049-0

M3 - Journal article

C2 - 22036019

VL - 378

SP - 2081

EP - 2087

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9809

ER -

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater